Modified nusinersen intrathecal injection method: inclusion of a septal needle-free closed infusion connector

Objective Nusinersen, an extremely expensive biologic drug (around 100,000 US$ per dose) that needs to be administered intrathecally, is approved for the treatment of 5q-spinal muscular atrophy (SMA). Because low muscle tone back muscles pediatric SMA patients, especially type 1 safe, effective, and fast execution sheath injection needed. Therefore, a modified intrathecal method was developed accordingly. This paper aims describe applicability safety this method. Methods The (MIIM) mainly includes septal needle-free closed infusion connector between lumbar puncture needle syringe, besides procedures routine puncture. Its were evaluated through clinical observation. Results A total 92 children with have successfully received nusinersen at our hospital using since 2019 without obvious adverse events related Based on feedback operators, advantages include injecting dose constant rate more stable fixation needle, as well making operator relaxed. However, compared method, procedure has additional steps. Conclusion effective safe inject when weighing pros cons, it may also used administering injections other medicines or patients strict requirements injection.